XOMA
XOMA Royalty Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+1.30%
vs ±17.0% implied · ×0.08
shaded = implied · ▲▼ = realized
XOMA Royalty has 1 disclosed supplier and 4 disclosed customers in SEC filings.
XOMA Royalty Corp
39.35
SentenceFor example, on December 15, 2023, we, through XRL, a newly formed, wholly-owned subsidiary, entered into a non-dilutive, non-recourse, royalty-backed loan for up to $140.0 million of capital with certain funds managed by the credit platform of Blue Owl Capital Inc.
SentenceFor example, in October 2023, Organon notified us of its intent to terminate the Organon License Agreement, which we assumed pursuant to the ObsEva IP Acquisition Agreement.
SentenceFor example, in 2017 we in-licensed (i) a fully human monoclonal antibody from XOMA Corporation ("XOMA"), who was acquired by Ligand Pharmaceuticals Incorporated on July 14, 2026, as well as (ii) a plasma kallikrein inhibitor portfolio from ActiveSite Pharmaceuticals ("ActiveSite") and in consideration for such licenses, we will continue to incur milestone payments and royalties as we progress product candidates through development.
SentenceIn May 2024, Day One sold its priority review voucher for $108.0 million and we received a payment of $8.1 million.
XOMA 10-Kaccession 0001104659-26-030872
Linked news
Expected move
No implied move.